Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Washington Terrace, UT
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Washington Terrace, UT
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Burlington, VT
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Alexandria, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Carrollton, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Carrollton, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Centreville, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Centreville, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Charlottesville, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Christiansburg, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Christiansburg, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fairfax, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fredericksburg, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Mclean, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Mclean, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Newport News, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Norfolk, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Richmond, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Roanoke, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Stafford, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Stafford, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Vienna, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Vienna, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Winchester, VA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Winchester, VA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Auburn, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Auburn, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Bellingham, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Bellingham, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Burien, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Burien, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Federal Way, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Federal Way, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Kirkland, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Mount Vernon, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Renton, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Renton, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Richland, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Richland, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Seattle, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Silverdale, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Silverdale, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Spokane, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Tacoma, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Wenatchee, WA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Huntington, WV
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Point Pleasant, WV
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Point Pleasant, WV
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Green Bay, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
La Crosse, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Madison, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Milwaukee, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Neenah, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Neenah, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Waukesha, WI
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Waukesha, WI
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Cheyenne, WY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Cheyenne, WY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Arecibo,
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Arecibo,
Click here to add this to my saved trials
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
Status: Enrolling
Updated:  1/15/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
Status: Enrolling
Updated: 1/15/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Muscle Atrophy in Patients With Severe Sepsis
Muscle Atrophy in Patients With Severe Sepsis
Status: Enrolling
Updated:  1/15/2016
The Ohio State University Medical Center - University Hospital
mi
from
Columbus, OH
Muscle Atrophy in Patients With Severe Sepsis
Muscle Atrophy in Patients With Severe Sepsis
Status: Enrolling
Updated: 1/15/2016
The Ohio State University Medical Center - University Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Arkansas Children's Hospital
mi
from
Little Rock, AR
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Childrens National Medical Center
mi
from
Washington,
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Children's Healtcare of Atlanta
mi
from
Atlanta, GA
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Children's Healtcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Johns Hopkins University
mi
from
Baltimore, MD
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Boston Children's Hospital
mi
from
Boston, MA
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated:  1/15/2016
Washington University
mi
from
St. Louis, MO
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Status: Enrolling
Updated: 1/15/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials